CSBio CSBio

X
[{"orgOrder":0,"company":"Almirall","sponsor":"University of Dundee","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Almirall and the University of Dundee announce a multi-target research collaboration to develop novel Targeted Protein Degraders medicines","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"SPAIN","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Almirall"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The collaboration aim to develop a novel class of medicines that target and degrade disease-causing proteins. The novel mechanism of action of PROTACs generates the possibility to eliminate disease relevant targets that were difficult to tackle with conventional approaches.

            Lead Product(s): Undisclosed

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: University of Dundee

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 08, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY